Mecamylamine

Last updated
Mecamylamine
Mecamylamine3.svg
Clinical data
Trade names Inversine, Vecamyl
AHFS/Drugs.com Consumer Drug Information
Routes of
administration 		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding 40%
Identifiers
  • (1S,2R,4R)-N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.433 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C11H21N
Molar mass 167.296 g·mol−1
3D model (JSmol)
  • N([C@@]2([C@@H]1CC[C@@H](C1)C2(C)C)C)C
  • InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3/t8-,9+,11+/m0/s1 Yes check.svgY
  • Key:IMYZQPCYWPFTAG-IQJOONFLSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Mecamylamine (INN, BAN; or mecamylamine hydrochloride (USAN); brand names Inversine, Vecamyl [1] ) is a non-selective, non-competitive antagonist of the nicotinic acetylcholine receptors (nAChRs) that was introduced in the 1950s as an antihypertensive drug. [2] In the United States, it was voluntarily withdrawn from the market in 2009 but was brought to market in 2013 as Vecamyl and eventually was marketed by Turing Pharmaceuticals. [3] [4]

Contents

Chemically, mecamylamine is a secondary aliphatic amine, with a pKaH of 11.2 [5]

Medical uses

Mecamylamine has been used as an orally-active ganglionic blocker in treating autonomic dysreflexia and hypertension, [6] but, like most ganglionic blockers, it is more often used now as a research tool.

Mecamylamine is also sometimes used as an antiaddictive drug to help people stop smoking tobacco, [7] and is now more widely used for this application than it is for lowering blood pressure. This effect is thought to be due to its blocking α3β4 nicotinic receptors in the brain. It has also been reported to bring about sustained relief from tics in Tourette syndrome when a series of more usually used agents had failed.[ medical citation needed ]

In a recent double-blind, placebo-controlled Phase II trial in Indian patients with major depression, (S)-mecamylamine (TC-5214) appeared to have efficacy as an augmentation therapy. This is the first substantive evidence that shows that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties. [8] [9] TC-5214 is currently in Phase III of clinical development as an add-on treatment and on stage II as a monotherapy treatment for major depression. The first results reported from the Phase III trials showed that TC-5214 failed to meet the primary goal and the trial did not replicate the effects that had been encouraging in the Phase II trial. [10] [11] Development is funded by Targacept and AstraZeneca. [12] It did not produce meaningful, beneficial results on patients as measured by changes on the Montgomery-Asberg Depression Rating Scale after eight weeks of treatment as compared with placebo.

In a recent double-blind, placebo-controlled Phase II trial in Indian patients with major depression, (S)-mecamylamine (TC-5214) appeared to have efficacy as an augmentation therapy. This is the first substantive evidence that shows that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties. [8] [9] TC-5214 is currently in Phase III of clinical development as an add-on treatment and on stage II as a monotherapy treatment for major depression. The first results reported from the Phase III trials showed that TC-5214 failed to meet the primary goal and the trial did not replicate the effects that had been encouraging in the Phase II trial. [13] [14] Development is funded by Targacept and AstraZeneca. [15] It did not produce meaningful, beneficial results on patients as measured by changes on the Montgomery-Asberg Depression Rating Scale after eight weeks of treatment as compared with placebo. In a recent double-blind, placebo-controlled Phase II trial in Indian patients with major depression, (S)-mecamylamine (TC-5214) appeared to have efficacy as an augmentation therapy. This is the first substantive evidence that shows that compounds where the primary pharmacology is antagonism to neuronal nicotinic receptors will have antidepressant properties. [8] [9] TC-5214 is currently in Phase III of clinical development as an add-on treatment and on stage II as a monotherapy treatment for major depression. The first results reported from the Phase III trials showed that TC-5214 failed to meet the primary goal and the trial did not replicate the effects that had been encouraging in the Phase II trial. [16] [17] Development is funded by Targacept and AstraZeneca. [18] It did not produce meaningful, beneficial results on patients as measured by changes on the Montgomery-Asberg Depression Rating Scale after eight weeks of treatment as compared with placebo.

Overdose

The LD50 for the HCl salt [19] in mice: 21 mg/kg (i.v.); 37 mg/kg (i.p.); 96 mg/kg (p.o.). [20]

Pharmacology

(S)-(+)-Mecamylamine dissociates more slowly from α4β2 and α3β4 receptors than does the (R)-(−)-enantiomer. [21]

A large SAR study of mecamylamine and its analogs was reported by a group from Merck in 1962. [22] Another, more recent SAR study was undertaken by Suchocki et al. [23]

A comprehensive review of the pharmacology of mecamylamine was published in 2001. [24]

History

Mecamylamine was brought to market by Merck & Co. in the 1950s; in 1996 Merck sold the asset to Layton Bioscience. [25] In 2002, Targacept acquired it from Layton, intending to repurpose it for CNS conditions. [26] Targacept voluntarily withdrew mecamylamine from the market in 2009 [27] for reasons not related to safety or efficacy. [28] Manchester Pharmaceuticals brought the drug back to market in 2013. [29] Retrophin acquired Manchester in 2014 [30] and after Martin Shkreli was forced out of Retrophin, in 2014 his new company, Turing Pharmaceuticals, acquired the rights to mecamylamine from Retrophin. [31]

See also

Related Research Articles

<span class="mw-page-title-main">Quetiapine</span> Atypical antipsychotic medication

Quetiapine, sold under the brand name Seroquel among others, is an atypical antipsychotic medication used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Despite being widely used as a sleep aid due to its sedating effect, the benefits of such use do not appear to generally outweigh the side effects. It is taken orally.

<span class="mw-page-title-main">Bupropion</span> Substituted cathinone medication mainly used for depression and smoking cessation

Bupropion, sold under the brand name Wellbutrin among others, is an atypical antidepressant primarily used to treat major depressive disorder and to support smoking cessation. It is also popular as an add-on medication in the cases of "incomplete response" to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant. Bupropion has several features that distinguish it from other antidepressants: it does not usually cause sexual dysfunction; it is not associated with weight gain and sleepiness, and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue. Bupropion, particularly the immediate release formulation, carries a higher risk of seizure than many other antidepressants, hence caution is recommended in patients with a history of seizure disorder.

<span class="mw-page-title-main">Doxepin</span> Medication to treat depressive disorder, anxiety disorders, chronic hives, and trouble sleeping

Doxepin is a medication belonging to the tricyclic antidepressant (TCA) class of drugs used to treat major depressive disorder, anxiety disorders, chronic hives, and insomnia. For hives it is a less preferred alternative to antihistamines. It has a mild to moderate benefit for sleeping problems. It is used as a cream for itchiness due to atopic dermatitis or lichen simplex chronicus.

<span class="mw-page-title-main">Viloxazine</span> Medication used to treat ADHD

Viloxazine, sold under the brand name Qelbree and formerly as Vivalan among others, is a selective norepinephrine reuptake inhibitor medication which is used in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults. It was marketed for almost 30 years as an antidepressant for the treatment of depression before being discontinued and subsequently repurposed as a treatment for ADHD. Viloxazine is taken by mouth. It was used as an antidepressant in an immediate-release form and is used in ADHD in an extended-release form.

<span class="mw-page-title-main">Amisulpride</span> Atypical antipsychotic and antiemetic medication

Amisulpride is an antiemetic and antipsychotic medication used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; and at higher doses by mouth to treat schizophrenia and acute psychotic episodes. It is sold under the brand names Barhemsys and Solian, Socian, Deniban and others. At very low doses it is also used to treat dysthymia.

<span class="mw-page-title-main">Vandetanib</span> Chemical compound

Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. The drug was developed by AstraZeneca who later sold the rights to Sanofi in 2015.

<span class="mw-page-title-main">Gepirone</span> Medication

Gepirone, sold under the brand name Exxua, is a medication used for the treatment of major depressive disorder. It is taken orally.

<span class="mw-page-title-main">Esketamine</span> Medication

Esketamine, also known as (S)-ketamine or S(+)-ketamine, is the S(+) enantiomer of ketamine. It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression. It is sold under the brand names Spravato, Ketanest, among others. Esketamine is the active enantiomer of ketamine in terms of NMDA receptor antagonism and is more potent than racemic ketamine.

<span class="mw-page-title-main">Ispronicline</span> Chemical compound

Ispronicline is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.

<span class="mw-page-title-main">Remacemide</span> Chemical compound

Remacemide is a drug which acts as a low-affinity NMDA antagonist with sodium channel blocking properties. It has been studied for the treatment of acute ischemic stroke, epilepsy, Huntington's disease, and Parkinson's disease.

<span class="mw-page-title-main">Bradanicline</span> Chemical compound

Bradanicline is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.

<span class="mw-page-title-main">TC-2216</span> Chemical compound

TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and was researched for the treatment of anxiety and depression. It was unsuccessful as a therapeutic but is still used in pharmacological research as an alpha4beta2-selective antagonist.

<span class="mw-page-title-main">Vortioxetine</span> Serotonin modulator antidepressant

Vortioxetine, sold under the brand names Trintellix and Brintellix among others, is a medication used to treat major depressive disorder. Its effectiveness is viewed as similar to that of other antidepressants. It is taken by mouth.

<span class="mw-page-title-main">Levomilnacipran</span> SNRI antidepressant drug

Levomilnacipran is an antidepressant which was approved in the United States in 2013 for the treatment of major depressive disorder (MDD) in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor (SNRI).

<span class="mw-page-title-main">Zibotentan</span> Chemical compound

Zibotentan is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.

Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.

<span class="mw-page-title-main">Buprenorphine/samidorphan</span> Combination drug formulation

Buprenorphine/samidorphan is a combination formulation of buprenorphine and samidorphan which is under development as an add on to antidepressants in treatment-resistant depression (TRD).

<span class="mw-page-title-main">Brilaroxazine</span> Experimental atypical antipsycotic

Brilaroxazine, also known as oxaripiprazole, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of neuropsychiatric and inflammatory disorders. It has currently completed the first of two phase III clinical trials for schizophrenia. Reviva Pharmaceuticals also intends to investigate brilaroxazine for the treatment of bipolar disorder, major depressive disorder, attention deficit hyperactivity disorder (ADD/ADHD), psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, as well as the inflammatory disorders pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), and psoriasis. The FDA granted brilaroxazine orphan drug designation for the treatment of PAH and IPF.

<span class="mw-page-title-main">Tezepelumab</span> Monoclonal antibody

Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma. Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.

<span class="mw-page-title-main">Dextromethorphan/bupropion</span> Combination medication

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). Its active components are dextromethorphan (DXM) and bupropion. Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial. It is taken as a tablet by mouth.

References

  1. ↑ "Mecamylamine". drugs.com . Retrieved May 15, 2015.
  2. ↑ Bacher I, Wu B, Shytle DR, George TP (November 2009). "Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders". Expert Opinion on Pharmacotherapy. 10 (16): 2709–2721. doi:10.1517/14656560903329102. PMID   19874251. S2CID   25690407.
  3. ↑ "Drug Profile: Mecamylamine - Targacept". AdisInsight. Springer Nature Switzerland AG.
  4. ↑ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 2017-10-16.
  5. ↑ Schanker LS, Shore PA, Brodie BB, Hogben CA (August 1957). "Absorption of drugs from the stomach. I. The rat". The Journal of Pharmacology and Experimental Therapeutics. 120 (4): 528–539. PMID   13476377.
  6. ↑ Soine TO (1966). Wilson CO, Gisvold O, Doerge RF (eds.). Textbook of Organic Medicinal and Pharmaceutical Chemistry (5th ed.). Philadelphia: Lippincott. pp. 468–546.
  7. ↑ Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR (July 2002). "Mecamylamine (Inversine): an old antihypertensive with new research directions". Journal of Human Hypertension. 16 (7): 453–457. doi:10.1038/sj.jhh.1001416. PMID   12080428.
  8. 1 2 3 Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, et al. (2008). "TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity". CNS Neuroscience & Therapeutics. 14 (4): 266–277. doi:10.1111/j.1755-5949.2008.00054.x. PMC   6494058 . PMID   19040552.
  9. 1 2 3 Rabenstein RL, Caldarone BJ, Picciotto MR (December 2006). "The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice". Psychopharmacology. 189 (3): 395–401. doi:10.1007/s00213-006-0568-z. PMID   17016705. S2CID   6395092.
  10. ↑ Carroll J (8 November 2011). "Key AZ/Targacept depression drug flunks first Phase III test". Fiercebiotech.com. Retrieved 2011-11-09.
  11. ↑ Hirschler B (8 November 2011). "AstraZeneca, Targacept drug fails depression test". Reuters.
  12. ↑ "AstraZeneca Pipeline as of the 27th of January 2011" . Retrieved 2011-11-09.
  13. ↑ Carroll J (8 November 2011). "Key AZ/Targacept depression drug flunks first Phase III test". Fiercebiotech.com. Retrieved 2011-11-09.
  14. ↑ Hirschler B (8 November 2011). "AstraZeneca, Targacept drug fails depression test". Reuters.
  15. ↑ "AstraZeneca Pipeline as of the 27th of January 2011" . Retrieved 2011-11-09.
  16. ↑ Carroll J (8 November 2011). "Key AZ/Targacept depression drug flunks first Phase III test". Fiercebiotech.com. Retrieved 2011-11-09.
  17. ↑ Hirschler B (8 November 2011). "AstraZeneca, Targacept drug fails depression test". Reuters.
  18. ↑ "AstraZeneca Pipeline as of the 27th of January 2011" . Retrieved 2011-11-09.
  19. ↑ In view of the time period when these data were generated, they presumably refer to the HCl salt of the racemic drug
  20. ↑ Spinks A, Young EH, Farrington JA, Dunlop D (December 1958). "The pharmacological actions of pempidine and its ethyl homologue". British Journal of Pharmacology and Chemotherapy. 13 (4): 501–520. doi:10.1111/j.1476-5381.1958.tb00246.x. PMC   1481871 . PMID   13618559.
  21. ↑ Papke RL, Sanberg PR, Shytle RD (May 2001). "Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 297 (2): 646–656. PMID   11303054.
  22. ↑ Stone CA, Torchiana ML, Meckelnberg KL, Stavorski J, Sletzinger M, Stein GA, et al. (July 1962). "Chemistry and Structure-Activity Relationships of Mecamylamine and Derivatives". Journal of Medicinal and Pharmaceutical Chemistry. 91 (4): 665–690. doi:10.1021/jm01239a001. PMID   14061006.
  23. ↑ Suchocki JA, May EL, Martin TJ, George C, Martin BR (March 1991). "Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system". Journal of Medicinal Chemistry. 34 (3): 1003–1010. doi:10.1021/jm00107a019. PMID   2002445.
  24. ↑ Young JM, Shytle RD, Sanberg PR, George TP (April 2001). "Mecamylamine: new therapeutic uses and toxicity/risk profile". Clinical Therapeutics. 23 (4): 532–565. doi:10.1016/s0149-2918(01)80059-x. PMID   11354389.
  25. ↑ Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR (July 2002). "Mecamylamine (Inversine): an old antihypertensive with new research directions". Journal of Human Hypertension. 16 (7): 453–457. doi:10.1038/sj.jhh.1001416. PMID   12080428.
  26. ↑ "Press release: Targacept, Inc. Acquires Marketed Drug To Expand Its CNS Portfolio | Evaluate". Targacept via Evaluate. August 27, 2002.
  27. ↑ "Notification letter from Targacept" (PDF). FDA. June 4, 2009.
  28. ↑ "Determination That INVERSINE (Mecamylamine Hydrochloride) Tablet and Six Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness". Federal Register. 28 July 2011.
  29. ↑ "Press release: Manchester Announces FDA Approval of Vecamyl". Manchester Pharamceuticals via Evaluate. May 1, 2013.
  30. ↑ Fidler B (13 February 2014). "Retrophin Shares Boom Following Manchester Pharma Buyout". Xconomy.
  31. ↑ Fidler B (10 August 2015). "Shkreli Leads $90M Round for New Startup, Turing Pharma | Xconomy". Xconomy.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.